Español
English
Revista de Osteoporosis y Metabolismo Mineral H0029
/
http://dx.doi.org/10.4321/S1889-836X2020000100001
Resumen|
PDF
Editorial
Protección ósea durante el cáncer de mama
Neyro JL, Cristóbal I, Palacios S
Publicado: 2023-03-02
Número de descargas:
3147
Número de visitas:
329
Citas:
0
Compártelo:
Palabras Clave:
Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287(2):216‐ 20.
Body JJ, editor. Tumor bone diseases and osteoporosis in cancer patients. Pathophysiology, diagnosis and therapy. New York: Marcel Dekker Inc.; 2000.
Kritz‐Silverstein D, Schneider DL, Sandwell J. Breast cancer and bone mass in older women: is bone density prescreening for mammography useful?. Osteoporos Int. 2006;17(8):1196‐201.
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7): 1570‐93.
Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer‐related bone complications. Clin Adv Hematol Oncol. 2009;7(5 Suppl 11):1‐31.
Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30 (6):763‐75.
Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79(7‐8):1179‐81.
Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med. 2005;165(5):552‐8.
Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. 2003; 13(10):698‐703.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor‐positive breast cancer: status report 2004. J Clin Oncol. 2005;23(3):619‐29.
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early‐stage breast cancer: 10‐year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135‐41.
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, et al. Long‐term follow‐up of the Intergroup Exemestane Study. J Clin Oncol. 2017; 35(22):2507‐14.
Gnant M, Mlineritsch B, Stoeger H, Luschin‐Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early‐stage breast cancer: 62‐month follow‐up from the ABCSG‐ 12 randomised trial. Lancet Oncol. 2011;12(7):631‐41.
Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, et al. Cancer therapy associated bone loss: implications for hip fractures in mid‐life women with breast cancer. Clin Cancer Res. 2011;17(3):560‐8.
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802‐ 10.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine‐ responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455‐62.
Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, et al. Letrozole compared with tamoxifen for elderly patients with endocrine‐responsive early breast cancer: the BIG 1‐98 trial. J Clin Oncol. 2008;26(12):1972‐9.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor‐positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17): 1262‐71.
Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8 (2):119‐27.
García‐Giralt N, Pineda‐Moncusí M, Ovejero D, Aymar I, Soldado‐Folgado J, Campodarve I, et al. Factores de riesgo de fractura incidente en pacientes con cáncer de mama tratadas con inhibidores de la aromatasa: cohorte BABLE. Rev Osteoporos Metab Miner. 2020;12(1):7‐13.
Artículos más populares
-
Licencia creative commons: Open Access bajo la licencia Creative Commons 4.0 CC BY-NC-SA
https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode
Editado en Madrid por:
